Thomas S. Uldrick, M.D.
Dr. Uldrick develops and directs early phase clinical studies and biomarker-driven natural history studies in KSHV-associated malignancies and cancer in people with HIV, including Kaposi sarcoma, multicentric Castleman disease, primary effusion lymphoma, primary CNS lymphoma, and anal cancer. He has published important studies on the pathogenesis of IL-6 related syndromes in the setting of HIV and KSHV co-infection, and HIV-associated cancers in resource-limited settings. Current therapeutic studies incorporate cytokine and growth factor manipulation, immune modulation, and targeting of reservoirs of gamma-herpesvirus infected lymphoid cells using monoclonal antibodies or virus activated cytotoxic therapy.
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell LymphomaOpen - RecruitingNCI Protocol ID NCI-16-C-0171Investigator Thomas S. Uldrick, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Anaida Widell, RN 301-451-3694
Phase I Study of Pembrolizumab in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmOpen - RecruitingNCI Protocol ID NCI-16-C-0066Investigator Thomas S. Uldrick, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Karen Aleman 301-435-5621
Pilot Study of Tocilizumab in Patients with Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - associated Multicentric Castleman DiseaseOpen - RecruitingNCI Protocol ID NCI-11-C-0233Investigator Thomas S. Uldrick, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Karen Aleman Fernandez 301.435.5621
Dr. Uldrick's major research interests are the natural history and management of virally associated malignancies that occur in the setting of HIV/AIDS and other immune disorders. Therapeutic studies focus on novel approaches to the treatment of several viral-associated malignancies using approaches that incorporate cytokine and growth factor manupulation and targeting of reservoirs of gamma-herpesvirus infected lymphoid cells using monoclonal antobodies or virus-activated cytotoxic therapy.
Active projects include: (1) Evaluation of the natural history of KSHV-associated disorders, including Kaposi sarcoma, KSHV-associated multicentric Castleman disease, primary effusion lymphoma, and a novel entity we described, KSHV-associated Inflammatory Cytokine Syndrome (KICS) (2) Early-phase treatment studies in KSHV-associated malignancies employing immune modulating, anti-angiogenic and virus-activated cytotoxic therapies (3) Evaluation of radiation-sparing approaches for HIV-associated primary CNS lymphoma, with an emphasis on long-term survival and neurocognitive functioning (4) Evaluation of human genomic alterations and gut associated lymphoid tissue in patients with anal cancer
Current collaborators include: Deborah Citrin, Radiation Oncology Branch, NCI Nancy Hessol, UCSF Frank Maldarelli, Drug Resistance Program, NCI Anisa Mosam, University of KwaZulu-Natal, South Africa Irini Sereti, Laboratory of Immunoregulation, NIAID Giovanna Tosato, Laboratory of Cellular Oncology, NCI Denise Whitby, Viral Oncology Section, NCI-Frederick HIV+ Tumor Molecular Characterization Project, Office of Cancer Genomics, NCI
An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.Clin Infect Dis. 51: 350-8, 2010. [ Journal Article ]
High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.Blood. 117: 6977-86, 2011. [ Journal Article ]
Phase II study of bevacizumab in patients with HIV-associated Kaposi"s sarcoma receiving antiretroviral therapy.J Clin Oncol. 30: 1476-83, 2012. [ Journal Article ]
Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma.AIDS. 28: 397-405, 2014. [ Journal Article ]
A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.J Acquir Immune Defic Syndr. 60: 150-7, 2012. [ Journal Article ]
Dr. Uldrick received his B.A. from the University of California at Berkeley, and his M.D. from the State University of New York, Downstate. He trained in internal medicine, hematology, and medical oncology at Columbia University. At Columbia, he completed an M.S. in biostatistics, with a focus on patient-oriented research, under a scholarship funded by an NIH-sponsored Clinical and Translational Science Award. Through the NIH-sponsored Fogarty program, he collaborated with Kaposi sarcoma (KS) researchers in South Africa on issues related to treatment of advanced KS in resource-limited settings. He has served on the NCI Lymphoma Steering Committee Primary Central Nervous System Lymphoma Working Group and participates on the AIDS Clinical Trials Group Independent Endpoint Review Committee for trials investigating KS therapies in sub-Saharan Africa.
|Qinghua (Roger) Ge||Data Manager|
|Kathryn Lurain M.D., M.P.H.||Clinical Fellow|
|Ramya Ramaswami M.D.||Clinical Fellow|
|Krista Waldon-Allen||Patient Care Coordinator (Contr)|
|Anaida Widell R.N.||Research Nurse|